在全球化能力建设方面，公司启动全球化战略，推进全球化的注册及临床开发能力建设。到2030年，公 司计划透过「海外授权+商业化」的双引擎驱动增长，加快国际化发展步伐。 格隆汇2月6日丨云顶新耀(01952.HK)宣布，中国国家药品监督管理局(NMPA)已批准维适平®(精氨酸艾 曲莫德片,VELSIPITY®)的新药上市申请(「新药上市申请」)，在中国用于治疗对传统治疗或生物制剂 应答不充分、失应答或不耐受的中度至重度活动性溃疡性结肠炎("UC")成人患者。 在疾病领域，公司聚焦肾科、自身免疫、急重症、心血管及眼科等核心方向，通过引进创新资产与自主 研发并行推进，到2030年形成高价值产品组合，并拓展其他蓝海领域的大单品。 在商业化平台建设上，公司已布局三款商业化产品，并着力建立全渠道商业化体系及药品全生命周期商 业化能力。公司计划到2028年实现收入规模超过100亿元人民币，而到2030年收入规模超过150亿元人民 币(其中现有管线销售收入约90亿元人民币而新引进管线销售收入约60亿元人民币)；收入的年复合增长 率预计在2025至2030年超过50%，2030年後保持超过15%。同时，商业化产品数量将提升至20 ...

Major Events - Cloudtop New Horizon (01952) has its original product, Nanfukang®, protected by patent ZL200980127272.5 in China, which is currently valid [1] - Linkang Biotechnology Group (00690) has reached a strategic cooperation with Wenzhou Medical University National Engineering Research Center and the People's Government of Ouhai District, Wenzhou [1] - Auhua Pharmaceutical (00013) announced that the new drug application for Savolitinib for treating gastric cancer patients with MET amplification has been accepted and included in priority review in China [1] - Fosun Pharma (02196) has initiated Phase I clinical trials for its integrated diagnosis and treatment nuclear medicine project SRT-007 within China [1] - Postal Savings Bank of China (01658) has received approval from the National Financial Supervision Administration for the absorption and merger with Postal Huai Wanjia Bank [1] - MicroPort Cardiac Devices-B (02160) has officially published the one-year follow-up results of the early feasibility study for AltaValveTM [1] Operating Performance - New Fire Technology Holdings (01611) reported an annual loss attributable to shareholders of HKD 9.212 million, a shift from profit to loss year-on-year [1] - Xingqian Development (00640) reported an annual net profit of approximately HKD 122 million, an increase of 21.7% year-on-year [1] - Zijin Mining Group (02899) expects a net profit attributable to shareholders of approximately RMB 51-52 billion for the fiscal year 2025, representing a year-on-year increase of about 59%-62% [1] - Zijin Gold International (02259) issued a profit warning, expecting a net profit attributable to shareholders of approximately USD 1.5-1.6 billion for 2025, a year-on-year increase of about 212%-233% [1]

Core Insights - By 2025, China's innovative pharmaceutical industry is projected to be the second largest globally, with approximately 30% of new drugs in development being from China, and the total amount of licensing agreements for domestic innovative drugs exceeding $100 billion, doubling from 2024 [1] - The Economist highlights that Chinese innovative drugs are at a critical point of globalization, with significant increases in global market share for Chinese pharmaceutical companies, and stock prices of Chinese biotech firms outperforming their US counterparts [1] - The rapid development is attributed to a decade of regulatory reforms, an ecosystem fostering innovation, and the advantages of China's large population and manufacturing capabilities [1] Industry Challenges - Despite impressive growth, the total market capitalization of Chinese biotech companies is only 15% of their US counterparts, with upfront licensing fees typically two-thirds lower than global averages [1] - Some pharmaceutical companies struggle with commercialization capabilities, which limits their potential value realization [1] Value Restructuring - Leading innovative pharmaceutical companies are advancing towards the top of the global value chain, with firms like Kangfang Biotech transitioning from licensing revenue to self-driven commercialization [2] - Companies are focusing on both global product development and building scalable commercialization platforms, which is becoming a core strategy for Chinese biotech firms to evolve into biopharma [2] Global Innovation Landscape - Chinese pharmaceutical companies are shifting from being fast followers to first movers, evidenced by significant business development deals with major international firms [3] - The mRNA technology sector is also seeing growth, with multiple companies advancing clinical trials and product development [3] mRNA Technology Potential - The value of mRNA technology is becoming increasingly evident, with major collaborations and acquisitions highlighting its potential [4] - Companies are pursuing dual strategies of in-licensing and out-licensing innovative assets to establish a strong global presence [4] Commercialization Challenges - The approval rate for new drugs is low, with only about 5% of drugs entering clinical trials successfully reaching the market, and only 20% of those achieving profitability [6] - Successful commercialization is critical for innovative drug companies, as it provides funding for future research and development [7] Market Dynamics - The traditional division of labor in the biopharmaceutical industry is evolving, with biotech companies gaining more negotiating power and opportunities for commercialization [9] - The market is expected to consolidate around platform companies with revenues between $5 billion and $10 billion, with a focus on integrating commercial strategies for innovative drugs [9] Commercialization Strategies - Companies like Cloudtop New Horizon are establishing integrated commercialization systems to enhance product growth and are actively pursuing partnerships to expand their market reach [10] - The company plans to introduce 3-5 significant products annually and aims to achieve substantial revenue growth by 2030 [10] Industry Evolution - The Chinese innovative pharmaceutical industry is undergoing a comprehensive upgrade, reshaping its value structure and positioning itself as a key player in the global biopharmaceutical landscape [11] - This transformation is moving China from a follower to a significant contributor and standard-setter in global biopharmaceutical innovation [11]

Core Insights - The article highlights the recognition of CloudTop New Health for its innovative strategies and achievements in the biopharmaceutical industry, winning multiple awards for its performance in drug development and commercialization [1][3]. Group 1: Awards and Recognition - CloudTop New Health received the "Annual Outstanding Innovative Pharmaceutical Newcomer" and "Annual Outstanding Drug Research and Development Innovation Enterprise" awards at the 2025 21st Century Health Industry Competitiveness Research [1]. - The company was also listed among the "Top 40 Leading Enterprises in China's Innovative Drug Export" at the 2025 Singapore Business and Charity Forum, showcasing its strengths in independent research and international clinical advancement [1]. Group 2: Product Performance - The product Renfukang® achieved sales revenue of 303 million yuan in the first half of 2025, marking an 81% year-on-year increase, with total sales expected to reach 1.2 to 1.4 billion yuan for the full year [3]. - The antibiotic product Yijia® generated sales of 143 million yuan in the first half of 2025, reflecting a 6% increase, with a significant 37% growth in sales to core hospitals [4]. Group 3: Strategic Developments - CloudTop New Health's 2030 strategy emphasizes a "BD cooperation + self-research" dual-driven approach to enhance its global presence and innovation capabilities [7]. - The company plans to expand its product pipeline to over 20 commercialized products by 2030, including Renfukang®, Weishiping®, Yijia®, and others, targeting a revenue scale exceeding 15 billion yuan [9]. Group 4: Future Outlook - The company anticipates a compound annual growth rate of over 50% from 2025 to 2030, with a goal to maintain growth rates above 15% post-2030 [9]. - CloudTop New Health aims to maximize commercial value through diverse methods, including independent research and licensing, while accelerating the global rollout of its innovative drugs [9].

Core Insights - The company, CloudTop New Horizon, has established a solid foundation over the past eight years through license-in strategies and aims to become a leading global biopharmaceutical company by 2030 with a revenue target of over 15 billion RMB and more than 20 commercialized products [1][2][10] Group 1: Strategic Development - The 2030 development strategy focuses on a dual approach of business development (BD) cooperation and independent research and development, targeting a revenue of over 15 billion RMB and over 20 commercialized products by 2030 [1][2][10] - The company plans to introduce 3-5 late-stage blockbuster products annually over the next five years, enhancing its product pipeline [3][10] - The strategic partnerships with Haisen Biopharmaceuticals will provide commercialization services for six approved products, generating service fees based on quarterly net sales [3][4] Group 2: Product Pipeline and Market Focus - The company will focus on key therapeutic areas such as nephrology, autoimmune diseases, critical care, cardiovascular, and ophthalmology, aiming to create a high-value product portfolio by 2030 [2][10] - The revenue from existing pipelines is projected to be around 9 billion RMB, with new pipeline sales expected to contribute approximately 6 billion RMB [2] - The company has successfully commercialized the drug Nefukang, which has rapidly gained market traction, demonstrating its commercial capabilities [7][10] Group 3: Research and Development - CloudTop New Horizon is advancing its self-developed mRNA platforms, including CAR-T and tumor vaccine platforms, with ongoing clinical trials [8][9] - The company plans to expand its R&D capabilities by introducing and incubating potential platforms, aiming to strengthen its core therapeutic areas [9][10] - The new reversible BTK inhibitor EVER001 has shown promising clinical data, indicating a steady global R&D progress [9] Group 4: Commercialization Strategy - The company is leveraging its integrated commercialization platform, which combines scientific and market insights, to enhance its operational efficiency and productivity [4][8] - The collaboration with Haisen Biopharmaceuticals exemplifies the company's ability to extend its commercialization capabilities to mature products [8] - The company aims to transition from a biotech firm to a comprehensive biopharmaceutical company with global competitiveness, reflecting a broader trend in the Chinese innovative drug industry [8][10]

Core Insights - The company, CloudTop New Medicine (1952.HK), has officially launched its 2030 development strategy aimed at becoming a leading global biopharmaceutical company within the next five years [1][3] - The strategy emphasizes a dual approach of "BD collaboration + self-research" to drive growth and value creation [1][4] Financial Projections - By 2030, the company plans to achieve revenue exceeding 15 billion RMB, with approximately 9 billion RMB from existing pipeline sales and around 6 billion RMB from newly introduced pipeline sales [1] - The expected compound annual growth rate (CAGR) from 2025 to 2030 is projected to exceed 50% [1] Product Pipeline and Focus Areas - The company will focus on key therapeutic areas including nephrology, autoimmune diseases, critical care, cardiovascular, and ophthalmology [1][4] - The goal is to commercialize over 20 products by 2030, including existing products like Nefukang®, Weishiping®, and others [1] R&D and Platform Development - The company aims to expand its mRNA platform to include in vivo CAR-T and mRNA tumor vaccine platforms, as well as siRNA and antibody platforms by 2030 [2] - Plans include building a commercialization system in Europe, the US, and emerging markets to drive growth through "overseas licensing + commercialization" [2] Strategic Partnerships - As the largest shareholder of NewBridge Bio (holding approximately 16%), the company plans to deepen collaboration with NewBridge to leverage its global resources and expertise [2] Management Insights - The board emphasizes that the 2030 strategy marks a significant milestone towards becoming a global leader in biopharmaceuticals [4] - The company plans to introduce 3-5 late-stage products annually and aims to accumulate over 20 high-value assets by 2030 [4] Commercialization and Market Strategy - The company has established a commercial system driven by integrated insights across medical, access, market, and sales [5] - The sales of Nefukang® surpassed 1 billion RMB in the first three quarters, showcasing the company's effective commercialization capabilities [5] Shareholder Confidence - On December 12, key executives and board members collectively purchased 846,659 shares, amounting to over 38 million HKD, reflecting strong confidence in the company's future [5] - Major shareholder Kangqiao Capital has committed to increasing its stake by up to 1% in the next three to six months, subject to market conditions [5]

Core Insights - The company, CloudTop New Medicine, held a strategic investor meeting on October 21, where the new chairman, Wu Yifang, outlined the company's strategic direction focusing on key initiatives such as strategic transactions, R&D innovation, and stakeholder management [1] - The controlling shareholder, Kangqiao Capital, will not reduce its stake in the company in the short term [1] - The company aims to enhance its product pipeline through self-research, licensing, acquisitions, and capital empowerment, with a goal to maximize commercial value and expand globally [1] Product Pipeline and Financial Projections - CloudTop New Medicine's product pipeline in key therapeutic areas such as nephrology, infectious diseases, and autoimmune diseases is entering a critical harvest period [1] - The company estimates that sales for its product, Naisankang®, will reach between RMB 1.2 billion and RMB 1.4 billion for the year, with a target of RMB 2.4 billion to RMB 2.6 billion by 2026 [1] - The product Weishiping® (Aicuo Mod) is expected to become the next significant product for the company [1] Future Plans and Collaborations - The company plans to introduce more than three heavyweight products in the next 6 to 12 months, with potential domestic sales peak exceeding RMB 10 billion, aiming for an overall domestic sales peak of over RMB 20 billion [2] - CloudTop New Medicine has signed a cooperation development letter of intent with I-Mab for the treatment of retinal diseases, which will strengthen collaboration in innovative R&D and international development [2] - The global anti-VEGF ophthalmic drug market is projected to reach approximately USD 40 billion by 2030, indicating significant growth potential in this sector [2]

Core Insights - CloudTop New Horizon (云顶新耀) held a strategic investor communication meeting on October 21, 2023, with key management team members present, including the new chairman Wu Yifang [2] - The company aims to enhance its product pipeline and maximize commercial value through a "dual-driven" strategy, focusing on self-research, licensing, acquisitions, and capital empowerment [2] - CloudTop plans to introduce more than three significant products in the next 6 to 12 months [2] Product Development - The company has entered a critical harvest period in its product pipeline, particularly in nephrology, infectious diseases, and autoimmune diseases, with sales revenue from the product Renfu Kang® nearing RMB 1 billion by Q3 2025 [3] - The product Weishiping® (艾曲莫德) is expected to become a significant growth driver for the company [3] - CloudTop is leveraging its mRNA tumor therapeutic vaccine platform and autologous CAR-T platform to strengthen its self-research capabilities and explore high-growth areas like ophthalmology [3] Clinical Trials and Collaborations - The new generation covalent reversible BTK inhibitor EVER001 (希布替尼) has shown promising results, with sustained benefits observed in patients during a 104-week follow-up period [3] - The company plans to initiate pivotal registration clinical trials for EVER001 in 2026 and is set to start human trials for its autologous CAR-T project by the end of 2025 [3] - CloudTop has signed a collaboration agreement with I-Mab for the development of the eye disease treatment VIS-101 in Greater China, South Korea, and Southeast Asia, aiming to enhance cooperation in innovative research and international development [4]

Core Insights - The company, CloudTop New Drug (01952.HK), held a strategic investor communication meeting on October 21, 2023, to discuss its latest strategic planning, R&D progress, and long-term development blueprint [1] Group 1: Leadership and Strategic Direction - The new chairman, Wu Yifang, will lead the board in setting the strategic direction and providing guidance to the executive team, focusing on strategic transactions, R&D innovation, and stakeholder management [2] - The major shareholder, Kangqiao Capital, has expressed confidence in the company's strategic outlook and will not reduce its stake in the short term, enhancing shareholder structure stability [2] Group 2: Strategic Focus and Market Expansion - The company will implement a "dual-engine" strategy, focusing on self-research and external collaborations to enrich its product pipeline and maximize commercial value [3] - CloudTop New Drug aims to accelerate its global expansion and self-research initiatives, particularly in key therapeutic areas such as nephrology, infectious diseases, and autoimmune diseases [3] Group 3: Product Pipeline and Financial Projections - The company’s products, including Nefukang® and Yijia®, have shown sustainable commercialization capabilities, with Nefukang® expected to achieve sales of approximately RMB 12 to 14 billion in 2025, and projected to grow to RMB 24 to 26 billion by 2026 [3] - The company plans to introduce over three significant products in the next 6 to 12 months, with potential domestic sales peak exceeding RMB 100 billion, aiming for an overall domestic sales peak of over RMB 200 billion [4] Group 4: R&D Innovations and Collaborations - The company is leveraging its mRNA cancer vaccine platform and CAR-T technology to establish a strong R&D foundation, with plans to enter high-growth areas such as ophthalmology [4] - A collaboration with I-Mab on the innovative product VIS-101 aims to enhance the company's presence in the ophthalmology market, which is projected to grow significantly [5][6] - VIS-101 has shown promising results in initial studies and is expected to enter Phase III trials by 2026, indicating a strong potential for market entry [5][6] Group 5: Overall Market Position and Future Outlook - The meeting highlighted the company's systematic progress in capital empowerment, innovation breakthroughs, and global expansion, reinforcing its competitiveness in the global innovative drug sector [6] - As core pipelines enter the value realization phase, the company is on a steady path toward becoming a leading comprehensive biopharmaceutical enterprise globally [6]

Core Insights - The company, CloudTop New Medicine (01952), held a strategic investor meeting on October 21, 2023, to discuss its latest strategic planning, R&D progress, and long-term development blueprint [1] Group 1: Leadership and Strategic Direction - The new chairman, Wu Yifang, will lead the board in setting the strategic direction and providing guidance to the management team, focusing on strategic transactions, R&D innovation, and stakeholder management [2] - The major shareholder, Kangqiao Capital, has expressed confidence in the company's strategic outlook and will not reduce its stake in the short term, which stabilizes the shareholder structure [2] Group 2: Dual-Engine Strategy and Market Expansion - The company will implement a "dual-engine" strategy, focusing on both in-house R&D and external collaborations, acquisitions, and capital empowerment to maximize commercial value [3] - Key therapeutic areas include nephrology, infectious diseases, and autoimmune diseases, with products like Nefukang® and Yijia® showing sustainable commercialization capabilities [3] - Nefukang® is projected to achieve sales of approximately RMB 1 billion in the first nine months of 2025, with an annual forecast of RMB 1.2 to 1.4 billion and a target of RMB 2.4 to 2.6 billion by 2026 [3] Group 3: R&D Advancements - The company is leveraging its mRNA cancer vaccine platform and autologous CAR-T platform to strengthen its R&D capabilities and explore high-growth areas like ophthalmology [4] - The new generation covalent reversible BTK inhibitor, EVER001, has shown promising clinical results and is set to enter pivotal trials in 2026 [4] - The company plans to introduce over three significant products in the next 6 to 12 months, with potential domestic sales peaks exceeding RMB 10 billion [4] Group 4: Strategic Collaboration with I-Mab - CloudTop New Medicine has signed a collaboration agreement with I-Mab for the development of VIS-101, a dual-specificity biologic for retinal diseases, enhancing its portfolio in the ophthalmology sector [5][6] - The global anti-VEGF ophthalmic drug market is projected to reach approximately $23 billion in 2024 and exceed $40 billion by 2030, indicating significant growth potential for innovative therapies [5][6] - The collaboration aims to accelerate the development of VIS-101 in the Asia-Pacific and the U.S., enhancing R&D efficiency and global expansion [6]